Testosterone and Visceral Fat: What You Need to Know

Testosterone and visceral fat are closely linked in ways that have real consequences for metabolic health. Visceral fat, the deep abdominal fat surrounding internal organs, is not merely a cosmetic concern; it drives insulin resistance, cardiovascular risk and hormonal disruption. Testosterone plays a direct role in regulating where the body stores and mobilises fat, and low levels are associated with greater visceral fat accumulation in men. This article explains the science behind this relationship, what clinical options exist, and when to seek medical advice.

What is visceral fat and why does it matter for your health?

Visceral fat is deep abdominal fat surrounding internal organs that releases inflammatory chemicals into the portal circulation, driving insulin resistance, cardiovascular disease and metabolic syndrome. Waist circumference above 94 cm in men or 80 cm in women signals increased metabolic risk.

Visceral fat is the metabolically active fat stored deep within the abdominal cavity, surrounding organs such as the liver, pancreas and intestines, and it carries significantly greater health risks than subcutaneous fat stored just beneath the skin. Unlike the fat you can pinch at the waist, visceral fat releases inflammatory chemicals and free fatty acids directly into the portal circulation, placing the liver and cardiovascular system under sustained metabolic stress.

Accumulation of visceral fat is strongly associated with a cluster of conditions collectively known as metabolic syndrome, which includes insulin resistance, raised blood pressure, dyslipidaemia and an elevated risk of type 2 diabetes and cardiovascular disease. NICE guidance on obesity and cardiovascular risk recognises central adiposity as an independent risk factor, and waist circumference is used alongside BMI in clinical assessment because it better reflects visceral fat burden.

A waist circumference above 94 cm in men and above 80 cm in women is considered a marker of increased metabolic risk, with thresholds of 102 cm and 88 cm respectively indicating substantially elevated risk, according to NHS and NICE guidance.^[1][3] These thresholds apply to white European populations. Lower thresholds are recommended for people of South Asian, Chinese, Japanese and other ethnic backgrounds, where metabolic risk increases at smaller waist sizes; your GP can advise on the appropriate threshold for you.^[4] Waist is measured at the midpoint between the lower rib and the top of the hip bone (iliac crest), taken at the end of a normal breath out.

NICE guidance (NG246) also recommends using waist-to-height ratio alongside BMI as a measure of central adiposity. A waist-to-height ratio below 0.5 is generally considered a lower-risk target for most adults, though clinical judgement and individual context always apply.

Understanding visceral fat is particularly relevant when considering hormonal influences on body composition, because hormones such as testosterone play a direct role in determining where the body preferentially deposits and mobilises fat. The relationship between testosterone and visceral fat is bidirectional, meaning each can influence the other in ways that have meaningful clinical consequences.

How does testosterone affect where your body stores fat?

Testosterone promotes fat breakdown in visceral depots and suppresses fat cell formation, favouring a leaner body composition. Cortisol, insulin and oestrogen all interact with these effects, so the broader hormonal environment matters.

Testosterone influences fat distribution by promoting lipolysis (the breakdown of stored fat) in visceral adipose tissue and by supporting the development and maintenance of lean muscle mass, which in turn raises basal metabolic rate. Androgen receptors are expressed in adipocytes throughout the body, and research suggests that visceral fat depots may be particularly responsive to androgenic signalling, making testosterone an important regulator of central body composition in men.^[9][10] The precise cellular mechanisms are still being characterised in the research literature, and the following represents the current scientific understanding rather than settled fact.

At a cellular level, testosterone is thought to suppress the differentiation of preadipocytes into mature fat cells (adipogenesis) and to promote the uptake of fatty acids into muscle rather than adipose tissue. It also appears to modulate the activity of lipoprotein lipase, an enzyme that governs fat storage in adipose depots. When testosterone levels are adequate, these mechanisms are believed to collectively favour a leaner, more metabolically favourable body composition.

In women, the picture is more complex. Testosterone is present at lower concentrations but still contributes to body composition regulation. Conditions associated with androgen excess, such as polycystic ovary syndrome (PCOS), can be associated with increased visceral fat accumulation. The mechanisms are not fully understood but are thought to involve insulin resistance and hyperandrogenism rather than a simple linear androgen effect; the role of altered cortisol metabolism has been proposed but is less well established.

Cortisol, insulin and oestrogen all interact with testosterone's effects on fat distribution. Chronic stress raises cortisol, which is thought to both suppress testosterone production and independently promote visceral fat deposition, though the relative contributions of each pathway in clinical practice are difficult to separate. This hormonal interplay means that addressing visceral fat often requires consideration of the broader endocrine environment rather than testosterone in isolation.

Does low testosterone cause belly fat to build up in men?

Low testosterone is associated with greater visceral fat accumulation, and the relationship is bidirectional: visceral fat raises aromatase activity, which converts testosterone to oestradiol and further lowers androgen levels. Hypogonadism is confirmed by symptoms plus two low morning testosterone readings.

Low testosterone is associated with increased visceral fat accumulation in men, and the relationship appears to be genuinely bidirectional rather than simply correlational. Epidemiological data, including evidence reviewed in European Association of Urology (EAU) guidelines on male hypogonadism, consistently show that men with lower serum testosterone levels carry more visceral adipose tissue and have larger waist circumferences than age-matched men with normal testosterone levels.

The mechanism works in both directions. Adipose tissue, particularly visceral fat, contains the enzyme aromatase, which converts testosterone into oestradiol. As visceral fat increases, aromatase activity rises, accelerating the conversion of testosterone and further lowering circulating androgen levels. This creates a self-reinforcing cycle in which low testosterone promotes fat gain, and fat gain further suppresses testosterone, making it progressively harder to break without intervention.

Hypogonadism, the clinical term for testosterone deficiency, is defined by the British Society for Sexual Medicine (BSSM) and NICE CKS guidance as a combination of symptoms and consistently low serum total testosterone, confirmed on at least two separate morning blood samples (ideally taken between 7 am and 11 am). UK guidance distinguishes between a total testosterone below 8 nmol/L (where deficiency is likely) and a level between 8 and 12 nmol/L (borderline), where symptoms, free testosterone and sex hormone-binding globulin (SHBG) levels all inform the clinical decision. Symptoms relevant to body composition include reduced muscle mass, increased fatigue, low mood and central weight gain, all of which can compound one another.

Initial investigation typically includes repeat morning total testosterone alongside luteinising hormone (LH), follicle-stimulating hormone (FSH), SHBG and prolactin. Thyroid function and a full blood count may also be checked. Reversible causes of low testosterone, including obesity itself, obstructive sleep apnoea and certain medicines such as opioids, should be identified and addressed before a diagnosis of primary hypogonadism is made.

It is important to note that not all men with central obesity have clinically low testosterone, and not all men with low testosterone develop significant visceral fat accumulation. Age-related decline in testosterone is gradual and normal, but when levels fall below the clinical threshold and symptoms are present, the contribution to visceral fat accumulation becomes clinically significant and warrants investigation.

Can raising testosterone levels help reduce visceral fat?

TRT reduces visceral fat and waist circumference in men with confirmed hypogonadism, with effects emerging gradually over months and enhanced by lifestyle changes. It is not indicated solely for fat reduction and carries contraindications requiring specialist assessment.

Testosterone replacement therapy (TRT) can reduce visceral fat in men with confirmed hypogonadism, and this effect is supported by clinical trial data and systematic reviews, though the magnitude of benefit varies between individuals and depends on baseline testosterone levels, duration of treatment and concurrent lifestyle factors. TRT is not a weight-loss treatment and is not indicated solely for the purpose of reducing body fat.

Randomised controlled trials and longer-term registry studies have demonstrated that TRT in hypogonadal men is associated with reductions in waist circumference, total body fat mass and visceral adipose tissue volume, alongside increases in lean muscle mass. These changes tend to emerge gradually over several months of treatment and are most pronounced in men who also make concurrent lifestyle changes. The BSSM and the EAU both acknowledge the metabolic benefits of TRT in appropriately selected patients.

TRT is available in several formulations in the UK, including transdermal gels (such as Testogel and Tostran) and long-acting intramuscular injections (such as Nebido). The choice of formulation is made by the prescribing clinician based on patient preference, adherence considerations and clinical factors. Implantable testosterone pellets are not a currently marketed formulation in the UK and should not be expected as a routine option; your prescriber can advise on what is available.

TRT is contraindicated in men with known or suspected prostate cancer or male breast cancer, untreated severe obstructive sleep apnoea and certain haematological conditions, and a thorough clinical assessment is essential before initiation.^[10] Baseline investigations before starting TRT typically include prostate-specific antigen (PSA) measurement and digital rectal examination (DRE) where clinically indicated by age or risk, full blood count and haematocrit, and liver function tests. Ongoing monitoring includes haematocrit (with dose adjustment or treatment pause if levels rise above approximately 0.54), PSA, and symptom review at regular intervals per BSSM and EAU guidance.

TRT suppresses the hypothalamic-pituitary-gonadal axis and reduces sperm production, so it is generally not appropriate for men who wish to preserve fertility. Men in this situation should be referred to a specialist, as alternatives such as gonadotrophin therapy may be considered. For men whose testosterone levels fall within the normal range, there is currently no robust evidence that raising testosterone further through pharmacological means produces meaningful reductions in visceral fat, and doing so outside a clinical indication carries risks. Any consideration of TRT should involve a specialist endocrinologist or urologist working within NHS or regulated private pathways.

Lifestyle changes that support healthy testosterone and reduce fat

Resistance exercise, adequate protein intake, 7 to 9 hours of sleep and stress management are the most evidence-supported lifestyle measures for improving both testosterone levels and visceral fat. Severe caloric restriction and excess alcohol can suppress testosterone production.

Structured resistance exercise is one of the most evidence-supported lifestyle interventions for both supporting testosterone levels and reducing visceral fat, and it should form the foundation of any non-pharmacological approach to improving body composition in men with or without borderline testosterone levels. Systematic reviews indicate that resistance training can reduce visceral adipose tissue and improve insulin sensitivity independently of overall weight loss, and it is associated with acute and longer-term favourable changes in androgen levels, though the size of these effects varies between studies.

Dietary quality plays an equally important role. Diets characterised by adequate protein intake, healthy fats (including monounsaturated and omega-3 fatty acids) and a moderate caloric deficit are associated with favourable changes in both testosterone and visceral fat. Very low-calorie diets and severe caloric restriction may suppress testosterone production, thought to be related to reduced availability of cholesterol (the precursor to steroid hormone synthesis) and broader suppression of the hypothalamic-pituitary-gonadal axis under conditions of significant energy deficit.^[13][14] Gradual, sustainable caloric reduction is therefore preferable to extreme restriction.

Sleep quality and duration have a direct impact on testosterone. The majority of daily testosterone secretion occurs during sleep, particularly during slow-wave sleep stages. Research, including a controlled study published in JAMA (Leproult and Van Cauter, 2011), found that restricting sleep to five hours per night for one week reduced daytime testosterone levels by 10 to 15 per cent in healthy young men.^[11] Targeting seven to nine hours of good-quality sleep per night is therefore a clinically meaningful recommendation for men concerned about testosterone and visceral fat.

Stress management is also relevant, given that chronically elevated cortisol is thought to suppress the hypothalamic-pituitary-gonadal axis and independently promote visceral fat deposition. Approaches such as mindfulness-based stress reduction, regular aerobic activity and limiting alcohol intake all contribute to a hormonal environment more conducive to healthy body composition. Alcohol impairs testosterone synthesis and disrupts sleep architecture. Alcohol consumption should remain within the UK Chief Medical Officers' low-risk guideline of no more than 14 units per week, spread across several days, with some alcohol-free days.^[12]

When should you speak to a GP about testosterone and weight concerns?

See a GP if persistent central weight gain accompanies symptoms such as fatigue, low libido, low mood or loss of muscle mass, especially in men aged 40 and over. Initial investigations include at least two morning total testosterone measurements alongside LH, FSH, SHBG and prolactin.

You should speak to your GP if you have persistent central weight gain alongside symptoms that may suggest testosterone deficiency, such as unexplained fatigue, reduced libido, loss of muscle mass, low mood or erectile dysfunction, particularly if these symptoms have developed gradually over months or years. A GP can arrange initial blood tests, including a morning serum total testosterone measurement, and assess whether further investigation or referral to an endocrinologist or urologist is appropriate.

The following situations warrant a GP appointment rather than self-management:

• Waist circumference consistently above 102 cm in men or 88 cm in women (or above the lower ethnicity-specific thresholds that apply to South Asian, Chinese and other groups), particularly alongside other metabolic risk factors

• Symptoms of hypogonadism as described above, especially in men aged 40 and over

• Unexplained weight gain despite reasonable dietary and activity habits

• A personal or family history of type 2 diabetes, cardiovascular disease or metabolic syndrome

• Concerns about the appropriateness of testosterone replacement therapy or questions about stopping it

Initial GP investigations for suspected testosterone deficiency typically include at least two repeat morning total testosterone measurements alongside LH, FSH, SHBG and prolactin. Thyroid function and a full blood count may also be requested. Your GP will consider reversible causes before referring to a specialist.

If you are already receiving TRT and experience symptoms such as significant breast tenderness, worsening urinary symptoms, polycythaemia (symptoms of which include headache, facial flushing and visual disturbance) or mood changes, contact your GP promptly rather than waiting for a routine review. These may indicate a need for dose adjustment or further monitoring.

For urgent symptoms such as chest pain, severe breathlessness or signs of a blood clot (including sudden leg swelling and pain), call 999 immediately. For non-emergency concerns outside GP hours, NHS 111 can provide guidance. Suspected adverse effects from any prescribed medicine, including testosterone preparations, can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, as one option for those exploring medically supervised approaches to body composition alongside GP care.

Scientific References

1. Overweight and obesity management (NG246): Identifying and assessing overweight, obesity and central adiposity.
2. Overweight and obesity management (NG246).
3. NG246 Full guideline, section 2 – Identification and classification: evidence statements and reviews.
4. NG246 Appendix A1: Summary of evidence from surveillance.
5. Calculate your waist to height ratio.
6. Body Mass Index, Waist Circumference, and Health Risk.
7. The hypogonadal-obesity cycle: role of aromatase in modulating the testosterone-estradiol shunt – Cohen PG.
8. Evidence for sex steroid inhibition of lipoprotein lipase in men – Ramirez ME et al..
9. Understanding the Role of Androgen Action in Female Adipose Tissue – Frontiers of Hormone Research.
10. Assessment report – Encyzix (testosterone undecanoate).
11. Effect of 1 Week of Sleep Restriction on Testosterone Levels in Young Healthy Men – Leproult R, Van Cauter E.
12. Alcohol consumption: advice on low risk drinking – UK Chief Medical Officers.
13. Caloric restriction increases serum testosterone concentrations in obese male subjects by two distinct mechanisms – Schulte DM et al..
14. Hungry runners – low energy availability in male endurance athletes and its impact on performance and testosterone: mini-review.

Frequently Asked Questions